Santoli: AI bull market almost surely needs tech stocks to recover to keep advancing
The road to bull-market glory does not run through Walmart and Berkshire Hathaway and Eli Lilly.
International news in seven languages
Topic
The road to bull-market glory does not run through Walmart and Berkshire Hathaway and Eli Lilly.
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Both sides of the Fed's dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its obesity pipeline.
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.